Patents by Inventor Jonathan L. Sessler

Jonathan L. Sessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5302714
    Abstract: The present invention involves, in addition to many unique substituted sapphyrins, a novel method for synthesizing sapphyrins with good efficiency and high yield. An improved 9-step synthesis of substituted sapphyrins, e.g., the two C.sub.2 symmetric sapphyrins, compounds 2 and 4 of FIG. 1C, is described herein. This synthesis involves as an important step the condensation between a tripyrrane diacid and a diformyl bipyrrole. The key tripyrrane component is prepared in three high-yield steps from readily available pyrrolic precursors and the bipyrrole portion is prepared in four steps from ethyl 3-methyl-4-methylpyrrole-2-carboxylate in roughly 33% yield overall.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: April 12, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Michael J. Cyr
  • Patent number: 5292414
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: April 20, 1992
    Date of Patent: March 8, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Murai Toshiaki, Gregory W. Hemmi
  • Patent number: 5272142
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: December 21, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
  • Patent number: 5256399
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: October 26, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
  • Patent number: 5252720
    Type: Grant
    Filed: January 21, 1992
    Date of Patent: October 12, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5162509
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: June 18, 1990
    Date of Patent: November 10, 1992
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
  • Patent number: 5159065
    Abstract: The present invention involves, in addition to many unique substituted sapphyrins, a novel method for synthesizing sapphyrins with good efficiency and high yield. An improved 9-step synthesis of substituted sapphyrins, e.g., the two C.sub.2 symmetric sapphyrins, compounds 2 and 4 of FIG. 1C, is described herein. This synthesis involves as an important step the condensation between a tripyrrane diacid and a diformyl bipyrrole. The key tripyrrane component is prepared in three high-yield steps from readily available pyrrolic precursors and the bipyrrole portion is prepared in four steps from ethyl 3-methyl-4-methylpyrrole-2-carboxylate in roughly 33% yield overall.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: October 27, 1992
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Michael J. Cyr
  • Patent number: 5120411
    Abstract: The present invention includes a method to produce singlet oxygen from molecular oxygen generated by reaction with a sapphyrin compound excited at an absorbing wavelength to form a triplet species. Specifically, the sapphyrin compound is an alkylated sapphyrin, most preferably diprotonated 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethylsapphyrin. Generation of the triplet species may be accomplished in an organic solvent, of which the most preferable solvents are chloroform, methanol or acetonitrile.Also encompassed within the present invention is a method to selectively produce singlet oxygen in an aqueous environment. A sapphyrin compound is incorporated within a membranous vesicle, the vesicle is illuminated with exciting light and the resultant excited triplet state sapphyrin compound reacts with molecular oxygen to produce singlet oxygen. Singlet oxygen was not generated external to the vesicle where the sapphyrin compound is present in an aqueous medium.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: June 9, 1992
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Anthony Harriman, Bhaskar G. Maiya
  • Patent number: 5041078
    Abstract: The present invention demonstrates a method of photodynamic inactivation of viruses having a membranous envelope, such as Herpes simplex type 1 and Human immunodeficiency type 1 viruses. The method uses substituted sapphyrin compounds to effect viral deactivation during radiation with light at or near the absorption wavelength of the sapphyrin compound. A highly reactive species selectively toxic to infectious agents is produced.One particular sapphyrin compound useful for the practice of the invention is 8,17-bis(carboxymethyl)-3,12,13,22-tetraethyl-2,7,18,23-tetramethylsapphyr in (Sapphyrin 2). The most preferred sapphyrin sapphyrin compound for the practice of the invention is 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethylsapphyrin (Sapphyrin 1).The method is particularly suitable for inactivation of viruses in blood and blood products.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: August 20, 1991
    Assignees: Baylor Research Foundation, a nonprofit corporation of the State of Texas, Board of Regents, The University of Texas System
    Inventors: J. Lester Matthews, Millard M. Judy, Joseph T. Newman, Frank Sogandares-Bernal, Jonathan L. Sessler, Anthony Harriman, Bhaskar G. Maiya
  • Patent number: 4935498
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: March 6, 1989
    Date of Patent: June 19, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai